As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

A uni­corn mul­ti­ple times over, Sana Biotech­nol­o­gy hit Nas­daq run­ning in Feb­ru­ary with its next-gen cell ther­a­pies still months away from the clin­ic. Now, Sana is look­ing to the fu­ture once again and clear­ing out some el­bow room for its man­u­fac­tur­ing team.

Sana has en­tered a long-term lease to de­vel­op a 163,000-square-foot man­u­fac­tur­ing fa­cil­i­ty in Cal­i­for­nia to ad­vance its late-stage clin­i­cal de­vel­op­ment and ear­ly com­mer­cial launch­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER